TrialNature communications2024

Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial.

Hu Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.